Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Limited treatment options are available for stage IIIB/IV non‐small cell lung cancer (NSCLC). Nivolumab, a programmed cell death‐1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. The present study investigated the effectiveness and safety of nivolumab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Hida, Toyoaki, Nishio, Makoto, Nogami, Naoyuki, Ohe, Yuichiro, Nokihara, Hiroshi, Sakai, Hiroshi, Satouchi, Miyako, Nakagawa, Kazuhiko, Takenoyama, Mitsuhiro, Isobe, Hiroshi, Fujita, Shiro, Tanaka, Hiroshi, Minato, Koichi, Takahashi, Toshiaki, Maemondo, Makoto, Takeda, Koji, Saka, Hideo, Goto, Koichi, Atagi, Shinji, Hirashima, Tomonori, Sumiyoshi, Naoki, Tamura, Tomohide
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448646/
https://ncbi.nlm.nih.gov/pubmed/28266091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13225
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados